Trailing-twelve-month (TTM) revenue is $1.58 Billion with a year-over-year growth of +8.41%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $382,884,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-23 |
| Q4 FY2025Period ended 2025-12-31 | $382,788,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-19 |
| Q1 FY2026Period ended 2026-03-31 | $393,706,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-23 |
| Q2 FY2026Period ended 2026-06-30 | $416,166,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-23 |
| TTM revenue | $1,575,544,000 |
Current P/S: $951,861,200 market capitalization ÷ $1,575,544,000 TTM revenue = 0.60x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $416.17M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T20:38:26.572Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Automotive Segments | $870M | $1.0B | $1.2B | $1.4B | $1.4B | $1.4B |
| Industrial Segments | N/A | N/A | $43M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| CHINA | $101M | $143M | $183M | $222M | $224M | $240M |
| CZECHIA | $38M | N/A | $49M | $70M |
$1.58B
$1.58 Billion
+8.41%
vs. $1.45B a year ago (TTM)
+7.39%
5 Year compound annual growth rate
1 Year
+8.41%
3 Year
+3.71%
5 Year
+7.39%
10 Year
+5.94%
15 Year
+15.90%
20 Year
+20.00%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $1.49B | +$38.49M | +2.64% |
| 2024 | $1.46B | ($12.95M) | (0.88%) |
| 2023 | $1.47B | +$264.42M | +21.95% |
| 2022 | $1.20B | +$158.51M | +15.15% |
| 2021 | $1.05B | +$133.05M | +14.57% |
| 2020 |
TTM Growth
+8.41%
3-Year CAGR
+3.71%
5-Year CAGR
+7.39%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T20:38:26.572Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $46M |
| N/A |
| N/A |
| Medical Segments | $43M | $42M | N/A | N/A | $50M | $50M |
|---|
| $90M |
| GERMANY | $59M | $67M | $75M | $102M | $106M | $114M |
|---|
| JAPAN | $58M | $64M | $58M | $61M | $54M | $48M |
|---|
| KOREA, REPUBLIC OF | $89M | $94M | $95M | $116M | $104M | $89M |
|---|
| MEXICO | N/A | N/A | $23M | $46M | $43M | $67M |
|---|
| Non-US | N/A | N/A | N/A | N/A | N/A | $985M |
|---|
| Other Countries | $192M | $224M | $132M | $177M | $193M | $195M |
|---|
| ROMANIA | N/A | $51M | $48M | $54M | $53M | $54M |
|---|
| SLOVAKIA | N/A | N/A | $35M | $45M | $55M | $55M |
|---|
| UNITED STATES | $378M | $404M | $472M | $537M | $504M | $513M |
|---|
| $913.10M |
| ($58.59M) |
| (6.03%) |
| 2019 | $971.68M | ($66.58M) | (6.41%) |
| 2018 | $1.04B | +$52.58M | +5.33% |
| 2017 | $985.68M | +$68.08M | +7.42% |
| 2016 | $917.60M | +$61.16M | +7.14% |
